Ann-Marie Roche

Director, Corporate Markets Marketing, Elsevier

Connect with Ann-Marie Roche on LinkedIn
Website: https://www.elsevier.com/

About the author: An experienced and passionate global marketing leader in creating useful, usable and enjoyable customer experiences. I started my career as a researcher and after joining Elsevier, I have had the opportunity to get closer to the fascinating world of Life Sciences, which I now use to identify and further explore key issues such as data as a service, AI, data extraction and personalized medicine. My goal is to engage with my audience and support knowledge sharing and discussion.

Posts by Ann-Marie Roche

AI precision medicine accelerates the search for rare disease treatment

Posted on September 20th, 2021 in AI & Data

AI and precision medicine are both changing drug discovery and development as we know it. Precision medicine that is powered by AI stands to be transformative, especially for the treatment of rare diseases. Elsevier was recently part of a collaboration that sought to demonstrate how AI precision medicine could lead researchers to new treatments for brain tumors faster.

Companies pledge to become net zero by 2040

Posted on August 31st, 2021 in Chemistry

The Intergovernmental Panel on Climate Change (IPCC) just released a special report on the impacts of climate change, and the findings suggest a very concerning picture of the future if greenhouse gas emissions continue at the current rate. The drastic changes in the weather, driving everything from wildfires to drought, are already giving us a preview of an increasingly turbulent future – and the knock-on effects can be seen in resulting crises like the large-scale loss of crops and homes.

Lessons learned from the Covid vaccine development process

Posted on August 23rd, 2021 in COVID-19

As the world’s focus has turned to getting the COVID-19 vaccines out as widely and rapidly as possible, it’s easy to almost forget about the incredible global effort that developed them in record time. But it is important to take some time to reflect on the process that got us here, so that we can learn from it and celebrate the amazing researchers whose work is now saving so many lives.

Accelerating synthetic chemistry with a predictive retrosynthesis solution

Posted on August 12th, 2021 in AI & Data

In most aspects of life, we think of “endless possibilities” as a good thing. But in science, the wealth of possibilities can be daunting. Pharmaceutical researchers typically start with a disease that they want to tackle, find a target, and then try to identify compounds which interact with that target. There may be around 200-300 drug candidates per project, and synthesis planning and execution usually takes four to eight weeks per drug candidate. This process requires many chemists and a huge, costly effort to proceed.